

Pfizer Research Grant Request for Proposals

Competitive Grant Program – Pfizer Internal Review Process

Real-World Data Generation with Elranatamab in Relapsed/Refractory Multiple Myeloma



Overview

This competitive grant program seeks to support research studies that focus on generating evidence on the **use of elranatamab in Multiple Myeloma (MM)** in the real world/clinical practice setting¹.

Patients with relapsed or refractory multiple myeloma (RRMM) generally experience poor response rates and survival outcomes, particularly those treated in later lines of therapy, including triple-class-exposed (TCE) patients². Given the recent approval of elranatamab and the limited real-world experience in TCE RRMM³⁻⁴, real-world data are needed to generate robust evidence on its effectiveness and safety in routine clinical practice.



Geographic Scope

Spain



Project Types and Area of Interest

Projects that will be considered for Pfizer support will focus on:

- *Real world evidence (RWE) and observational studies assessing safety, effectiveness, and treatment patterns*
- *Comparative and sequencing analyses evaluating outcomes across prior therapies and lines of treatment*
- *Subgroup and disparity research focused on populations under represented in clinical trials*
- *Patient centered outcomes research, including Patient-Reported Outcomes (PROs), caregiver burden, and adherence*
- *Translational and biomarker research to understand mechanisms of response, resistance, and relapse*



Key Milestones

Submission Deadline

Anticipated Grant Award Notification

Anticipated Project Start Date/Duration



22 MAY 2026



JUN 2026



SEP 2026



Funding Range and Project Length

Total available budget related to this RFP is approximately 250,000€.

Individual projects requesting up to 120,000€ will be considered, although smaller requests (around 60,000€) are also encouraged.

Projects are encouraged to begin from September 2026 onwards, for a maximum duration of 26 months.

I. Eligibility

Geographic Scope:

- Spain

Applicant Eligibility Criteria

- The institution and Principal Investigator (PI) must be based in Spain.
- Only organizations are eligible to receive grants, not individuals or medical practice groups (i.e., an independent group of physicians not affiliated with a hospital, academic institution, or professional society).
- If the project involves multiple departments within an institution and/or between different institutions / organizations / associations, all institutions must have a relevant role and the requesting organization must have a key role in the project.
- The PI must have a medical or postdoctoral degree (MD, PhD, or equivalent), an advanced nursing degree (BSN with a MS/PhD), or a degree in Pharmacy, Physiotherapy, or Social Work.
- The applicant must be the PI or an authorized designee of such individual (e.g., PI's research coordinator).
- The PI must be an employee or contractor of the requesting organization.
- Requesting organization must be legally able to receive award funding directly from Pfizer International LLC. We strongly recommend that applicants confirm this with their organization or institution prior to submitting an application. Grants awarded to organizations that are subsequently found to be unable to accept funding directly from Pfizer International LLC may be subject to rescission.

II. Requirements

Primary Area of Interest:

- Oncology - Hematologic - RES

General Area of Interest for this RFP:

Projects that will be considered for Pfizer support will focus on:

- Safety and efficacy of elranatamab in the context of real-world use
- Outpatient administration of elranatamab and alternative CRS/ICANS mitigation strategies
- Impact of prior treatments (BsAb, ADC) on elranatamab outcomes, and wash-out period between treatments
- Clinical outcomes of elranatamab according to treatment sequencing for RRMM
- Collection and assessment of PROs, caregiver burden, and treatment/prophylaxis adherence
- Infection patterns, timing, types, and management strategies including Ig replacement therapy (IV and/or SQ) while on elranatamab treatment
- Assessment of elranatamab use and outcomes across patient subgroups under-represented in clinical trials (e.g. elderly patients, those with renal impairment)
- Characterizing clinical and biological determinants of response to elranatamab, including features associated with primary refractoriness, early versus delayed response, and disease relapse, as well as the identification and validation of predictive and response biomarkers in real-world clinical practice.

Target Audience


- The primary audience(s) targeted for this project will be healthcare professionals focused on multiple myeloma (e.g. hematologists, specialty nurses, internists)

Expected Approximate Monetary Range of Grant Applications

IMPORTANT: Grants will be distributed following a fully executed agreement and submission of Final Protocol, Documentation of IRB/IEC Approval, Regulatory Approval (if applicable), Exemption or Waiver.

- Projects requesting **up to 120,000€ per project** for initiatives with large potential reach and impact will be considered. Smaller projects - around 60,000€ - are also encouraged.
- The **total available budget** related to this RFP is **approximately 250,000€**.
- Award amounts include direct costs, institutional overhead costs (capped at 28% per Pfizer policy), and indirect costs.

Key Dates:



IMPORTANT: Be advised applications submitted after the due date will not be reviewed.

*Please note the deadline is 23:59 Eastern Standard Time (e.g., New York, GMT -5)

How to Submit:

IMPORTANT: Please read this section carefully since applications submitted not following these instructions will not be accepted and will be cancelled.

- Please go to www.cybergrants.com/pfizer/Research and sign in.
 - Note: there are individual portals for each grant application type. Please be sure to use the URL above.
 - First-time users should click “Create your password”.
- Click the “**Start A New Research Grant Application**” button.
- Requirements for submission:
 - Complete all required sections of the online application
 - **IMPORTANT:** Upload proposal (see Appendix) in the Proposal/Protocol field.
- In the application:
 - For the question “**Competitive Grant?**” select “**Yes**”
 - Select the following Primary Area of Interest: **Oncology - Hematologic - RES**
 - Select the following Competitive Grant Program Name: **2026 ONC RRMM ES RES**

Questions:

- If you encounter any technical difficulties with the website, please click [here](#) or the “Technical Questions” link at the bottom of the page in cybergrants.
- Please click [here](#) to view “Frequently Asked Questions” regarding the Competitive Grant Program.
- If you have questions regarding this RFP, please direct them in writing to the Grant Officer, Nicola Fenderico (Nicola.Fenderico@Pfizer.com), with the subject line “2026 ONC RRMM ES RES”

Review and Approval Process

- Grant requests received in response to a general RFP are reviewed by Pfizer to make final grant decisions.

Mechanism by which Applicants will be Notified:

- All applicants will be notified via email by the dates noted above.
- Applicants may be asked for additional clarification during the review period.

Grant Agreements:

- If your grant is approved, your institution will be required to enter into a written grant agreement with Pfizer. Please click [here](#) to view the core terms of the agreement.
- Under Pfizer's competitive grant program, modifications to grant agreements will not be reviewed unless a genuine conflict exists as between applicable law and the terms of the relevant grant agreement. Applicant is encouraged to share the core terms with counsel for approval prior to submitting an application.
- Except where prohibited by applicable law and, in any case, subject to review by Pfizer Legal, payment of grant funding may only be paid to the grantee organization.

References

1. SmPc elranatamab <https://www.pfizerpro.es/medicamentos>
2. Mateos MV. et al. LocoMMotion: a study of real-life current standards of care in triple-class –exposed patients with relapsed/refractory multiple myeloma—2 year follow-up (final analysis). *Leukemia* (2024)
3. Tsang, C. et al. Comparison of outcomes with elranatamab and real world treatments in the UK for triple class exposed relapsed and refractory multiple myeloma. *BMC Cancer* (2025)
4. Malard F, et al. Elranatamab monotherapy in the real-world setting in relapsed- refractory multiple myeloma: results of the French compassionate use program on behalf of the IFM. *Blood Cancer Journal* (2024)

About Pfizer Grants

Pfizer supports the global healthcare community's independent initiatives (e.g., research, quality improvement or education) to improve patient outcomes in areas of unmet medical need that are aligned with Pfizer's medical and/or scientific strategies.

Pfizer's competitive grant program involves a publicly posted general Request for Proposal (RFP) that provides detail regarding a general area of interest, sets timelines for review and approval, and uses an internal Pfizer review process to make final grant decisions. Organizations are invited to submit an application addressing the research gaps as outlined in the specific RFP.

For all Investigator Sponsored Research (ISRs) and general research grants, the grant requester (and ultimately the grantee) is responsible for the design, implementation, sponsorship, and conduct of the independent initiative supported by the grant, including compliance with any regulatory requirements. Pfizer must not be involved in any aspect of study protocol or project development, nor the conduct or monitoring of the research program. An ISR grant request cannot be submitted for a study that has already commenced and was not originally supported by Pfizer.

Appendix

IMPORTANT: RFP Submission Requirements

Applications will be accepted via the online portal listed in the How to Submit section. Project Proposals/Protocols should be single-spaced using Calibri 12-point font and 1-inch margins. Note there is a 15-page limit exclusive of references. When uploading your Full Proposal please ensure it addresses the following sections:

Goals and Objectives

- Provide the main goal of the study and the study population (if applicable). Provide a detailed definition that is directly linked to the primary objective.

Assessment of Need for the Project

- This should reflect your study rationale. Provide a brief description of the medical/scientific question and the rationale of how this trial or study addresses the question.

Target Audience

- Describe the primary audience(s) targeted for this project. For Investigator Sponsored Clinical Trials, please specify the age, gender and other demographic information for trial population.
- Also indicate whom you believe will directly benefit from the project outcomes. Describe the overall population size as well as the size of your sample population.

Project Design and Methods

- Describe concisely the research design and methods for achieving the stated goals. For a clinical interventional study, include inclusion/exclusion criteria, treatment plan and statistical plan.

Innovation

- Explain what measures you have taken to assure that this project idea is original and does not duplicate other projects. Describe how this project builds upon existing work, pilot projects, or ongoing projects developed either by your institution or other institutions related to this project.

Evaluation and Outcomes

- Specify type and frequency of safety, efficacy, and/or outcome measures. Also indicate the method(s) used to assess measures.
- Provide a publication plan describing intended submission of abstracts to (a) congress(es) or intended submission of (a) publication(s) to peer-reviewed journals.

Anticipated Project Timeline

- Provide an anticipated timeline for your project including project start/end dates.
- An ISR grant request cannot be submitted for a study that has already commenced and was not originally supported by Pfizer.

Additional Information

- If there is any additional information you feel Pfizer should be aware of concerning the importance of this project, please summarize here.
- Early-career applicants: Letter(s) of support from mentor(s) and collaborators describing how the award will advance the applicant's career.

Organization Detail

- This information is used to assess the capability of the organizational resources available to perform the effort proposed. Identify the facilities to be used [laboratory, animal, clinical and "other"]. If appropriate, indicate their capacities, pertinent capabilities, relative proximity and extent of availability to the project.

Budget Detail

- The budget amount requested must be in Euro (EUR).
- While estimating your budget please keep the following items in mind:
- General organizational running costs such as legal fees, insurance, heating, and lighting etc. should be included in an Institutional Overhead (if required). These costs are not specific to a grant request and therefore, should not appear as line items in budgets. However, costs that are specific to the study (e.g., some countries require insurance to be taken out on a per-study basis for clinical research) would be acceptable to be included as line items.
- The inclusion of these costs cannot cause the amount requested to exceed the budget limit set forth in the RFP.
- Pfizer does not provide funding for capital purchases (infrastructure expenses such as equipment, purchases of software or software licenses, technology or bricks and mortar). Equipment hire/leasing is acceptable and may be included in project budget.
- It should be noted that grants awarded through GMGP cannot be used to purchase Pfizer therapeutic agents (prescription or non-prescription).
- Pfizer maintains a company-wide, maximum allowed overhead rate of 28% for independent studies and projects. Please [click here](#) for details.

Required Documents

- Project Plan or Proposal
- Initial Study Protocol